Abstract
Oxidative damage is a major feature of Alzheimers disease pathophysiology. Instead of succumbing to these oxidative abnormalities, neurons upregulate antioxidant defenses, which suggest a novel balance in oxidant homeostasis in Alzheimers disease. Evidence indicates that in the initial phase of Alzheimers disease development, amyloid-β deposition and hyperphosphorylated τ are consequences of oxidative stress and function as a primary line of antioxidant defense. However, during the progression of the disease, the antioxidant activity of both agents evolves into pro-oxidant, representing a typical gain-of-function transformation. This transformation is due to an increase in reactive species and a decrease in clearance mechanisms. However, the notion that amyloid-β and hyperphosphorylated t function as protective components in the early stages of Alzheimers disease brings into serious question the rationale of current therapeutic strategies aimed to remove both amyloid-β and hyperphosphorylated τ.
Keywords: alzheimer disease, amyloid, oxidative stress, reactive oxygen species, tau
Current Neurovascular Research
Title: A Second Look into the Oxidant Mechanisms in Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Paula I. Moreira, Catarina R. Oliveira, Maria S. Santos, Akihiko Nunomura, Kazuhiro Honda, Xiongwei Zhu, Mark A. Smith and George Perry
Affiliation:
Keywords: alzheimer disease, amyloid, oxidative stress, reactive oxygen species, tau
Abstract: Oxidative damage is a major feature of Alzheimers disease pathophysiology. Instead of succumbing to these oxidative abnormalities, neurons upregulate antioxidant defenses, which suggest a novel balance in oxidant homeostasis in Alzheimers disease. Evidence indicates that in the initial phase of Alzheimers disease development, amyloid-β deposition and hyperphosphorylated τ are consequences of oxidative stress and function as a primary line of antioxidant defense. However, during the progression of the disease, the antioxidant activity of both agents evolves into pro-oxidant, representing a typical gain-of-function transformation. This transformation is due to an increase in reactive species and a decrease in clearance mechanisms. However, the notion that amyloid-β and hyperphosphorylated t function as protective components in the early stages of Alzheimers disease brings into serious question the rationale of current therapeutic strategies aimed to remove both amyloid-β and hyperphosphorylated τ.
Export Options
About this article
Cite this article as:
Moreira I. Paula, Oliveira R. Catarina, Santos S. Maria, Nunomura Akihiko, Honda Kazuhiro, Zhu Xiongwei, Smith A. Mark and Perry George, A Second Look into the Oxidant Mechanisms in Alzheimers Disease, Current Neurovascular Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567202053586758
DOI https://dx.doi.org/10.2174/1567202053586758 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sigma-2 Receptor Ligands: Neurobiological Effects
Current Medicinal Chemistry Role of Sigma Receptors in Methamphetamine-Induced Neurotoxicity
Current Neuropharmacology Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Nitroxyl (HNO): A Possible Strategy for Fighting Cancer
Current Topics in Medicinal Chemistry Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§
Current Medicinal Chemistry FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Nicotine, Body Weight and Potential Implications in the Treatment of Obesity
Current Topics in Medicinal Chemistry Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology TRP Channels in Vascular Disorders
Current Topics in Medicinal Chemistry Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Calcium-Sensing Receptor (CaSR) in Human Brains Pathophysiology: Roles in Late-Onset Alzheimers Disease (LOAD)
Current Pharmaceutical Biotechnology Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design